[Yung Shin] Announcement of the Approval of Non-Compete Restriction Removal for Directors at the 2026 Annual General Meeting
Key facts
- [Yung Shin] Announcement of the Approval of Non-Compete Restriction Removal for Directors at the 2026 Annual General Meeting
- Yung Shin Pharmaceutical announced that the 2026 AGM approved the removal of non-compete restrictions for three directors. Director Li Fang-chuan will hold a concurrent position at De-Zhen Pharmaceutical (Jiangsu) Co., Ltd., with no material impact on the company's finances.
- Source: PR Times
- Date: May 27, 2026
Direct answer
Yung Shin Pharmaceutical announced that the 2026 AGM approved the removal of non-compete restrictions for three directors. Director Li Fang-chuan will hold a concurrent position at De-Zhen Pharmaceutical (Jiangsu) Co., Ltd., with no material impact on the company's finances.
- Citation
- [Yung Shin] Announcement of the Approval of Non-Compete Restriction Removal for Directors at the 2026 Annual General Meeting (May 27, 2026), PR Times
- Source
- PR Times
- Date
- May 27, 2026
Yung Shin Pharmaceutical announced that the 2026 AGM approved the removal of non-compete restrictions for three directors. Director Li Fang-chuan will hold a concurrent position at De-Zhen Pharmaceutical (Jiangsu) Co., Ltd., with no material impact on the company's finances.
📋 Article Processing Timeline
- 📰 Published: May 27, 2026 at 09:00
- 🔍 Collected: May 28, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 31, 2026 at 19:09 (83h 9m after Collected)
2. Names and titles of directors permitted to engage in competitive activities:
(1) Director: Li Ling-jin
(2) Director: Representative of Bio-Tech Holdings Co., Ltd.: Li Fang-yu
(3) Director: Representative of Yung-Chuan Investment Co., Ltd.: Li Fang-chuan
3. Items permitted: Investing in or managing companies with the same or similar business scope as the company, and serving as a director or manager.
4. Duration: During the term of office as a director of the company.
5. Resolution details (pursuant to Article 209 of the Company Act): Passed as proposed after a vote by shareholders representing at least two-thirds of the total issued shares.
6. Directors involved in competitive activities in mainland China:
Director: Representative of Yung-Chuan Investment Co., Ltd.: Li Fang-chuan
7. Name and position in the mainland Chinese entity: Director of De-Zhen Pharmaceutical (Jiangsu) Co., Ltd.
8. Address of the mainland Chinese entity: No. 191, Jinyang West Road, Lujia Town, Kunshan City, Jiangsu Province.
9. Business scope of the mainland Chinese entity: Pharmaceutical wholesale, pharmaceutical retail, and food sales.
10. Impact on the company's financial and business operations: No material impact.
11. Investment amount and shareholding ratio in the mainland Chinese entity: None.
12. Other matters: None.
FAQ
What is Article 209 of the Taiwan Company Act?
It requires directors to obtain shareholder approval before engaging in competitive business activities that overlap with the company's scope.
What are the key facts in this article?
Yung Shin Pharmaceutical announced that the 2026 AGM approved the removal of non-compete restrictions for three directors. Director Li Fang-chuan will hold a concurrent position at De-Zhen Pharmaceutical (Jiangsu) Co., Ltd., with no material impact on the company's finances.
What is the direct answer?
Yung Shin Pharmaceutical announced that the 2026 AGM approved the removal of non-compete restrictions for three directors. Director Li Fang-chuan will hold a concurrent position at De-Zhen Pharmaceutical (Jiangsu) Co., Ltd., with no material impact on the company's finances.